Amedeo Smart

Free Medical Literature Service


 

Amedeo

Bacterial Infections and Mycoses

  Free Subscription

Articles published in
Am J Respir Crit Care Med
    February 2025
  1. RUMPF CH, Janssen T, Hait RJ, Romme K, et al
    Mucoid Staphylococcus aureus - Prevalence and Association with Lung Function in People with Cystic Fibrosis.
    Am J Respir Crit Care Med. 2025 Feb 7. doi: 10.1164/rccm.202407-1474.
    >> Share

    December 2024
  2. DERENDINGER B, Mochizuki TK, Marcelo D, Shankar D, et al
    C-reactive Protein-based Screening of People with Tuberculosis Symptoms: A Diagnostic Accuracy Study.
    Am J Respir Crit Care Med. 2024 Dec 6. doi: 10.1164/rccm.202405-1000.
    >> Share

    November 2024
  3. EPELBAUM O, Marinelli T, Haydour QS, Pennington KM, et al
    Treatment of Invasive Pulmonary Aspergillosis and Preventive and Empirical Therapy for Invasive Candidiasis in Adult Pulmonary and Critical Care Patients. An Of fi cial American Thoracic Society Clinical Practice Guideline.
    Am J Respir Crit Care Med. 2024 Nov 18. doi: 10.1164/rccm.202410-2045.
    >> Share


  4. Erratum: Who Transmits Tuberculosis to Whom: A Cross-Sectional Analysis of a Cohort Study in Lima, Peru.
    Am J Respir Crit Care Med. 2024;210:1280.
    >> Share

    September 2024
  5. LORE NI, Gramegna A, de Pretis S, Di Marco F, et al
    Single-Cell RNA Sequencing Shows that Circulating Monocytes Enriched in IFN Signaling Are Associated with Nontuberculous Mycobacteria Pulmonary Disease in Cystic Fibrosis.
    Am J Respir Crit Care Med. 2024;210:834-837.
    >> Share

    August 2024
  6. MORGAN SJ, Nichols DP, Ni W, Hong G, et al
    Elexacaftor/Tezacaftor/Ivacaftor Markedly Reduces Aspergillus fumigatus in Cystic Fibrosis.
    Am J Respir Crit Care Med. 2024 Aug 27. doi: 10.1164/rccm.202406-1128.
    >> Share

  7. ZAVALA S, Stout JE
    A Balancing Act: Finding the Right Dose of Pyrazinamide to Treat Tuberculosis.
    Am J Respir Crit Care Med. 2024 Aug 22. doi: 10.1164/rccm.202406-1262.
    >> Share

  8. AULD SC, Barczak AK, Bishai W, Coussens AK, et al
    Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the 2(nd) International Post-Tuberculosis Symposium.
    Am J Respir Crit Care Med. 2024 Aug 14. doi: 10.1164/rccm.202402-0374.
    >> Share

  9. ROCHE SM, Ottewill C, Mulpeter R, Brown K, et al
    Delayed Tuberculosis Paradoxical Reaction Associated with TNF Inhibitors.
    Am J Respir Crit Care Med. 2024 Aug 12. doi: 10.1164/rccm.202402-0464.
    >> Share

    July 2024
  10. COHEN T, Colijn C, Warren JL
    Approaches for M. tuberculosis Transmission Inference Based on Genomic Data.
    Am J Respir Crit Care Med. 2024 Jul 17. doi: 10.1164/rccm.202404-0835.
    >> Share

  11. LEE WC
    Pairs or Paradoxes: Questioning Assumptions in Tuberculosis Transmission Research.
    Am J Respir Crit Care Med. 2024 Jul 17. doi: 10.1164/rccm.202405-0958.
    >> Share

  12. XU AY, Velasquez GE, Zhang N, Chang VK, et al
    Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized, Controlled Clinical Trial.
    Am J Respir Crit Care Med. 2024 Jul 16. doi: 10.1164/rccm.202401-0165.
    >> Share

  13. MOSSOP M, Ish-Horowicz J, Hughes D, Dobra R, et al
    Chronicity Counts: The Impact of Pseudomonas aeruginosa, Staphylococcus aureus, and Coinfection in Cystic Fibrosis.
    Am J Respir Crit Care Med. 2024;210:240-242.
    >> Share

    June 2024
  14. CRABBE A
    Intracellular Pseudomonas aeruginosa: An Overlooked Reservoir in the Lungs of People with Cystic Fibrosis?
    Am J Respir Crit Care Med. 2024;209:1421-1423.
    >> Share

  15. MALET K, Faure E, Adam D, Donner J, et al
    Intracellular Pseudomonas aeruginosa within the Airway Epithelium of Cystic Fibrosis Lung Tissues.
    Am J Respir Crit Care Med. 2024;209:1453-1462.
    >> Share

  16. FEYS S, Cardinali-Benigni M, Lauwers HM, Jacobs C, et al
    Profiling Bacteria in the Lungs of Patients with Severe Influenza Versus COVID-19 with or without Aspergillosis.
    Am J Respir Crit Care Med. 2024 Jun 12. doi: 10.1164/rccm.202401-0145.
    >> Share

    May 2024
  17. ZHANG M, Yang C, Guo Y
    Aspergilloma in Cavity.
    Am J Respir Crit Care Med. 2024 May 31. doi: 10.1164/rccm.202312-2348.
    >> Share

  18. CRABBE A
    Moving Beyond Antibiotics: Exploring the Potential of an Anti-Virulence Monoclonal Antibody Against Pseudomonas aeruginosa in Bronchiectasis.
    Am J Respir Crit Care Med. 2024 May 23. doi: 10.1164/rccm.202405-0974.
    >> Share

  19. LONG MB, Gilmour A, Kehl M, Tabor D, et al
    A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of Pseudomonas aeruginosa in Patients with Bronchiectasis.
    Am J Respir Crit Care Med. 2024 May 16. doi: 10.1164/rccm.202308-1403.
    >> Share

  20. MARTINEZ-GARCIA MA
    The Heterogeneous World of Non-Tuberculous Mycobacteria in Bronchiectasis.
    Am J Respir Crit Care Med. 2024 May 15. doi: 10.1164/rccm.202405-0936.
    >> Share

  21. GILMORE A, Ortiz J
    Pneumococcal Vaccines.
    Am J Respir Crit Care Med. 2024;209:P5-P7.
    >> Share

  22. LI L, Henkle E, Youngquist BM, Seo S, et al
    Serum Cell-Free DNA-based Detection of Mycobacterium avium Complex Infection.
    Am J Respir Crit Care Med. 2024;209:1246-1254.
    >> Share

  23. MCSHANE PJ, Brunton AE, Choate R, Marmor M, et al
    The Impact of Tobacco Smoking in Bronchiectasis: Data from the United States Bronchiectasis and NTM Research Registry.
    Am J Respir Crit Care Med. 2024 May 7. doi: 10.1164/rccm.202402-0466.
    >> Share

  24. DAVIES GR
    Reconsidering the Role of Isoniazid in Drug-resistant Tuberculosis.
    Am J Respir Crit Care Med. 2024 May 1. doi: 10.1164/rccm.202403-0628.
    >> Share

    April 2024
  25. MATHEMA B, Burzynski J
    One Half of the Pair: Prioritizing Tuberculosis Transmitters for Early Detection.
    Am J Respir Crit Care Med. 2024 Apr 30. doi: 10.1164/rccm.202404-0699.
    >> Share

  26. AKSAMIT TR, Locantore N, Addrizzo-Harris D, Ali J, et al
    Five-Year Outcomes Among U.S. Bronchiectasis and Nontuberculous Mycobacterial Registry Patients.
    Am J Respir Crit Care Med. 2024 Apr 26. doi: 10.1164/rccm.202307-1165.
    >> Share

  27. DRAIN PK
    Another Step Closer to Genomic-informed Therapeutic Dosing for Tuberculosis Drugs.
    Am J Respir Crit Care Med. 2024 Apr 22. doi: 10.1164/rccm.202403-0566.
    >> Share

  28. GAUSI K, Ignatius EH, De Jager V, Upton C, et al
    High-Dose Isoniazid Lacks EARLY Bactericidal Activity Against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized, Phase 2 Clinical Trial.
    Am J Respir Crit Care Med. 2024 Apr 2. doi: 10.1164/rccm.202311-2004.
    >> Share

  29. ZHANG M, Luo Q, Li X, Mu X, et al
    Pulmonary Artery Pseudoaneurysm Caused by Pulmonary Mucormycosis.
    Am J Respir Crit Care Med. 2024;209:879-880.
    >> Share

    March 2024
  30. AHMAD S, Wrennall JA, Goriounova AS, Sekhri M, et al
    Specific Inhibition of Orai1-mediated Calcium Signalling Resolves Inflammation and Clears Bacteria in an Acute Respiratory Distress Syndrome Model.
    Am J Respir Crit Care Med. 2024;209:703-715.
    >> Share

  31. VERMA R, Silva KED, Rockwood N, Wasmann RE, et al
    A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.
    Am J Respir Crit Care Med. 2024 Mar 5. doi: 10.1164/rccm.202309-1583.
    >> Share

    February 2024
  32. TREVISI L, Brooks MB, Becerra MC, Calderon RI, et al
    Who Transmits Tuberculosis to Whom: A Cross-Sectional Analysis of a Cohort Study in Lima, Peru.
    Am J Respir Crit Care Med. 2024 Feb 28. doi: 10.1164/rccm.202307-1217.
    >> Share

  33. LIN CF, Wu YW, Liao WA, Lin CY, et al
    Right Atrial Angiosarcoma with Embolic Lung Metastases Masquerading as Atypical Pneumonitis.
    Am J Respir Crit Care Med. 2024;209:325-328.
    >> Share

  34. XIA L, Hantrakun V, Teparrukkul P, Wongsuvan G, et al
    Plasma Metabolomics Reveals Distinct Biological and Diagnostic Signatures for Melioidosis.
    Am J Respir Crit Care Med. 2024;209:288-298.
    >> Share

    January 2024
  35. MAC AOGAIN M, Xaverius Ivan F, Jaggi TK, Richardson H, et al
    Airway 'Resistotypes' and Clinical Outcomes in Bronchiectasis.
    Am J Respir Crit Care Med. 2024 Jan 25. doi: 10.1164/rccm.202306-1059.
    >> Share

  36. LAGHLAM D, Giraud F, Benghanem S
    Severe Pulmonary and Nasopharyngeal Candida Krusei Infection in Cocaine-induced Vasculopathy.
    Am J Respir Crit Care Med. 2024 Jan 11. doi: 10.1164/rccm.202305-0828.
    >> Share

    December 2023
  37. TSIN WEN Y, Cheng AC, Podin Y
    Precision Medicine for Sepsis Management in Low- and Middle-Income Countries - Melioidosis as a Model?
    Am J Respir Crit Care Med. 2023 Dec 6. doi: 10.1164/rccm.202311-2056.
    >> Share

  38. NATHANI A, Tauquir A, Khan S, Arrossi AV, et al
    Unusual Presentation of Pneumocystis jirovecii Pneumonia in an Immunocompromised Host.
    Am J Respir Crit Care Med. 2023;208:e44-e46.
    >> Share

    November 2023
  39. FEYS S, Hoenigl M, Gangneux JP MD, PhD, FECMM, Verweij PE, et al
    Fungal Fog in Viral Storms: Necessity for Rigor in Aspergillosis Diagnosis and Research.
    Am J Respir Crit Care Med. 2023 Nov 16. doi: 10.1164/rccm.202310-1815.
    >> Share

  40. LONG DR, Holmes EA, Goss CH, Singh PK, et al
    Cell-Free DNA Detects Pseudomonas aeruginosa Lung Infection in Modulator-treated People with Cystic Fibrosis.
    Am J Respir Crit Care Med. 2023;208:944-947.
    >> Share

    October 2023
  41. ANIDI IU, Kirenga B, Fennelly KP
    Pulmonary Rehabilitation for Post-Tuberculosis Lung Disease.
    Am J Respir Crit Care Med. 2023 Oct 5. doi: 10.1164/rccm.202309-1571.
    >> Share

  42. ROCHESTER CL, Alison JA, Carlin B, Holland AE, et al
    Reply to: Pulmonary Rehabilitation for Post-Tuberculosis Lung Disease.
    Am J Respir Crit Care Med. 2023 Oct 5. doi: 10.1164/rccm.202309-1714.
    >> Share

  43. SAEKI Y, Moriyama Y, Araki Y, Oda A, et al
    Gas Gangrene after Thoracic Drainage for Empyema with Tension Pneumothorax.
    Am J Respir Crit Care Med. 2023;208:814-815.
    >> Share

    August 2023
  44. HILL H, Mitsi E, Nikolaou E, Blizard A, et al
    A Randomised Controlled Trial of Nasal Immunisation with Live Virulence Attenuated Streptococcus pneumoniae Strains Using Human Infection Challenge.
    Am J Respir Crit Care Med. 2023 Aug 9. doi: 10.1164/rccm.202302-0222.
    >> Share

    July 2023
  45. OTTEWILL C, Dolan L, Lopez Bailen E, Roycroft E, et al
    Immunosuppressed Pets as a Conduit for Zoonotic Tuberculosis.
    Am J Respir Crit Care Med. 2023 Jul 25. doi: 10.1164/rccm.202304-0734.
    >> Share

    June 2023
  46. ALBRICH WC, Lamoth F
    Viral-associated Pulmonary Aspergillosis: Have We Finally Overcome the Debate of Colonization Versus Infection?
    Am J Respir Crit Care Med. 2023 Jun 22. doi: 10.1164/rccm.202306-1022.
    >> Share

  47. VANDERBEKE L, Jacobs C, Feys S, Resendiz-Sharpe A, et al
    A Pathology-based Case Series of Influenza- and COVID-19-associated Pulmonary Aspergillosis: The Proof Is in the Tissue.
    Am J Respir Crit Care Med. 2023 Jun 13. doi: 10.1164/rccm.202208-1570.
    >> Share

  48. PATANKAR S, Cruz AT, Douglas-Jones B, Garcia-Prats A, et al
    Making the Case for All-Oral, Shorter Regimens for Children with Drug-Resistant Tuberculosis.
    Am J Respir Crit Care Med. 2023 Jun 5. doi: 10.1164/rccm.202304-0670.
    >> Share

  49. BRUST JCM
    "Weighting" the Evidence: How Much Bedaquiline Is Enough?
    Am J Respir Crit Care Med. 2023;207:1423-1424.
    >> Share

    May 2023
  50. MITNICK CD, Nunn AJ
    Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?
    Am J Respir Crit Care Med. 2023;207:1269-1270.
    >> Share

  51. KURBATOVA EV, Phillips PPJ, Dorman SE, Sizemore EE, et al
    A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.
    Am J Respir Crit Care Med. 2023;207:1376-1382.
    >> Share

  52. LIU Y, Xu J, Wang C, Lu B, et al
    Pulmonary Mucormycosis with Rib Involvement in an Immunocompromised Patient.
    Am J Respir Crit Care Med. 2023;207:1393-1394.
    >> Share

    April 2023
  53. BORGES DE ALMEIDA CP, Mitnick CD
    Intervening on Social Determinants for Better Outcomes in Pediatric Tuberculosis Management.
    Am J Respir Crit Care Med. 2023 Apr 19. doi: 10.1164/rccm.202303-0601.
    >> Share

  54. MARTINEZ L, Zar HJ
    Reply to: Intervening on Social Determinants for Better Outcomes in Pediatric Tuberculosis Management.
    Am J Respir Crit Care Med. 2023 Apr 19. doi: 10.1164/rccm.202304-0629.
    >> Share

  55. MASEKELA R, Mandalakas AM
    Pediatric Post-TB Lung Disease: Ready for Prime Time?
    Am J Respir Crit Care Med. 2023;207:975-977.
    >> Share

    February 2023
  56. TREVISI L, Hernan MA, Mitnick CD, Khan U, et al
    Effectiveness of Bedaquiline Use Beyond Six Months in Patients with Multidrug-Resistant Tuberculosis.
    Am J Respir Crit Care Med. 2023 Feb 21. doi: 10.1164/rccm.202211-2125.
    >> Share

  57. MARTINEZ L, Gray DM, Botha M, Nel M, et al
    The Long-Term Impact of Early-Life Tuberculosis Disease on Child Health: A Prospective Birth Cohort Study.
    Am J Respir Crit Care Med. 2023 Feb 6. doi: 10.1164/rccm.202208-1543.
    >> Share

    January 2023
  58. STAGG HR, Thompson JA, Lipman MCI, Sloan DJ, et al
    Forgiveness Is the Attribute of the Strong: Nonadherence and Regimen Shortening in Drug-sensitive Tuberculosis.
    Am J Respir Crit Care Med. 2023;207:193-205.
    >> Share

  59. VELASQUEZ GE, Nahid P
    Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-Susceptible Tuberculosis.
    Am J Respir Crit Care Med. 2023 Jan 11. doi: 10.1164/rccm.202212-2262.
    >> Share

    December 2022
  60. DOOLEY KE, Hendricks B, Gupte N, Barnes G, et al
    Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-containing Regimens for Drug-sensitive TB: 12-Week Results.
    Am J Respir Crit Care Med. 2022 Dec 1. doi: 10.1164/rccm.202208-1475.
    >> Share


  61. Erratum: Response to Hypoxia and the Ensuing Dysregulation of Inflammation Impacts Mycobacterium tuberculosis Pathogenicity.
    Am J Respir Crit Care Med. 2022;206:1434.
    >> Share

  62. HENRIQUES-NORMARK B, Narciso AR
    An Experimental Human Colonization Model with Pneumococcal Serotype 3 has the Potential to be Used for Vaccine Studies.
    Am J Respir Crit Care Med. 2022;206:1312-1314.
    >> Share

  63. ROBINSON RE, Mitsi E, Nikolaou E, Pojar S, et al
    Human Infection Challenge with Serotype 3 Pneumococcus.
    Am J Respir Crit Care Med. 2022;206:1379-1392.
    >> Share

    November 2022
  64. BEENTJES D, Shears RK, French N, Neill DR, et al
    Mechanistic Insights into the Impact of Air Pollution on Pneumococcal Pathogenesis and Transmission.
    Am J Respir Crit Care Med. 2022;206:1070-1080.
    >> Share

    October 2022
  65. CHECKLEY W
    Tuberculosis, Wildfires, and Case-Crossover Studies: An Epidemiological Trifecta?
    Am J Respir Crit Care Med. 2022 Oct 31. doi: 10.1164/rccm.202210-1936.
    >> Share

    September 2022

  66. Erratum: Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling.
    Am J Respir Crit Care Med. 2022;206:800-801.
    >> Share

  67. LINDE LR, Readhead A, Barry PM, Balmes JR, et al
    Tuberculosis Diagnoses Following Wildfire Smoke Exposure in California.
    Am J Respir Crit Care Med. 2022 Sep 14. doi: 10.1164/rccm.202203-0457.
    >> Share

    June 2022
  68. MARAIS BJ, Graham SM
    The Value of Chest Radiography in Tuberculosis Preventive Treatment (TPT) Screening in Children and Adolescents.
    Am J Respir Crit Care Med. 2022 Jun 2. doi: 10.1164/rccm.202205-1023.
    >> Share

    May 2022
  69. DOWDY DW
    Coughing is Not Required to Transmit Mycobacterium tuberculosis: Another Nail in the Coffin.
    Am J Respir Crit Care Med. 2022 May 25. doi: 10.1164/rccm.202204-0645.
    >> Share

  70. HUANG CC, Tan Q, Becerra MC, Calderon R, et al
    The Contribution of Chest Radiography to the Clinical Management of Children Exposed to Tuberculosis.
    Am J Respir Crit Care Med. 2022 May 24. doi: 10.1164/rccm.202202-0259.
    >> Share

  71. DINKELE R, Gessner S, McKerry A, Leonard B, et al
    Aerosolization of Mycobacterium tuberculosis by Tidal Breathing.
    Am J Respir Crit Care Med. 2022 May 18. doi: 10.1164/rccm.202110-2378.
    >> Share

  72. TOBIN MJ
    Fiftieth Anniversary of Uncovering the Tuskegee Syphilis Study: The Story and Timeless Lessons.
    Am J Respir Crit Care Med. 2022;205:1145-1158.
    >> Share

  73. DE JAGER V, Gupte N, Nunes S, Barnes GL, et al
    Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial.
    Am J Respir Crit Care Med. 2022;205:1228-1235.
    >> Share

  74. ESMAIL A, Oelofse S, Lombard C, Perumal R, et al
    An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study).
    Am J Respir Crit Care Med. 2022;205:1214-1227.
    >> Share

  75. OLIVIER KN, Prevots DR
    HALTing Nontuberculous Mycobacteria in Cystic Fibrosis Centers: Is There Something in the Water?
    Am J Respir Crit Care Med. 2022;205:982-983.
    >> Share

  76. GROSS JE, Caceres S, Poch K, Hasan NA, et al
    Investigating Nontuberculous Mycobacteria Transmission at the Colorado Adult Cystic Fibrosis Program.
    Am J Respir Crit Care Med. 2022;205:1064-1074.
    >> Share

    April 2022
  77. SHAKU MT, Bishai WR
    Mycobacterium tuberculosis: A Pathogen That Can Hold its Breath a Long Time.
    Am J Respir Crit Care Med. 2022 Apr 20. doi: 10.1164/rccm.202203-0432.
    >> Share

  78. BUCSAN AN, Veatch A, Singh DK, Akter S, et al
    Response to Hypoxia and the Ensuing Dysregulation of Inflammation Impacts Mycobacterium tuberculosis Pathogenicity.
    Am J Respir Crit Care Med. 2022 Apr 12. doi: 10.1164/rccm.202112-2747.
    >> Share

  79. PITTET LF, Fritschi N, Tebruegge M, Dutta B, et al
    Bacillus Calmette-Guerin Skin Reaction Predicts Enhanced Mycobacteria-Specific T-Cell Responses in Infants: A Post Hoc Analysis of a Randomized Controlled Trial.
    Am J Respir Crit Care Med. 2022;205:830-841.
    >> Share

    March 2022
  80. LANGE C, Barry Iii CE, Horsburgh CR Jr
    Treatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel.
    Am J Respir Crit Care Med. 2022 Mar 23. doi: 10.1164/rccm.202202-0393.
    >> Share

    February 2022
  81. COOKSON W, Moffatt M, Rapeport G, Quint J, et al
    A Pandemic Lesson for Global Lung Diseases: Exacerbations are Preventable.
    Am J Respir Crit Care Med. 2022 Feb 22. doi: 10.1164/rccm.202110-2389.
    >> Share

    January 2022
  82. SCHLUGER NW
    Of Mice and Men, Women, and Children: Using Animal Models to Inform Tuberculosis Clinical Trials of Novel Agents.
    Am J Respir Crit Care Med. 2022 Jan 31. doi: 10.1164/rccm.202112-2866.
    >> Share

  83. CHO HJ, Yu JH
    Quincke's Sign of Janeway Lesion in Infective Endocarditis.
    Am J Respir Crit Care Med. 2022 Jan 27. doi: 10.1164/rccm.202110-2362.
    >> Share

  84. O'DONNELL M, Mathema B
    Expanding the Tuberculosis Cascade of Care to Treat Undiagnosed and Subclinical Tuberculosis in High-Burden Settings.
    Am J Respir Crit Care Med. 2022;205:149-151.
    >> Share

    December 2021
  85. KAUSHIK A, Ammerman NC, Tasneen R, Lachau-Durand S, et al
    Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy.
    Am J Respir Crit Care Med. 2021 Dec 23. doi: 10.1164/rccm.202012-4541.
    >> Share

  86. FENNELLY KP, Martinez L, Mandalakas AM
    Tuberculosis: First in Flight.
    Am J Respir Crit Care Med. 2021 Dec 14. doi: 10.1164/rccm.202111-2513.
    >> Share

  87. SHIMIZU T, Watanabe S, Murata A, Kasahara K, et al
    Bronchial Cast Hiding Pulmonary Tuberculosis.
    Am J Respir Crit Care Med. 2021 Dec 3. doi: 10.1164/rccm.202105-1306.
    >> Share

  88. SCHLUGER NW
    Using Isoniazid More Safely and More Effectively: The Time Is Now.
    Am J Respir Crit Care Med. 2021;204:1248-1250.
    >> Share

  89. WATERS V
    Two Steps Forward: Improving the Management of Cystic Fibrosis Pulmonary Exacerbations.
    Am J Respir Crit Care Med. 2021;204:1245-1247.
    >> Share

    November 2021
  90. BUNYASI EW, Middelkoop K, Koch A, Hoosen Z, et al
    Molecular Detection of Airborne Mycobacterium tuberculosis in South African High Schools.
    Am J Respir Crit Care Med. 2021 Nov 9. doi: 10.1164/rccm.202102-0405.
    >> Share

  91. ADJOBIMEY M, Behr MA, Menzies D
    Individualized Treatment Duration in Tuberculosis Treatment: Precision versus Simplicity.
    Am J Respir Crit Care Med. 2021;204:1013-1014.
    >> Share

    October 2021
  92. ATRE SR, Jagtap JD, Faqih MI, Dumbare YK, et al
    Tuberculosis Pathways to Care and Transmission of Multidrug-Resistance in India.
    Am J Respir Crit Care Med. 2021 Oct 27. doi: 10.1164/rccm.202012-4333.
    >> Share

  93. NOURSADEGHI M, Gupta RK
    New Insights into the Limitations of Host-Transcriptional Biomarkers of Tuberculosis.
    Am J Respir Crit Care Med. 2021 Oct 27. doi: 10.1164/rccm.202109-2146.
    >> Share

    September 2021
  94. LU S, Kolls JK
    Early Antibiotics in Cystic Fibrosis: Lessons from the Cystic Fibrosis Pig Model.
    Am J Respir Crit Care Med. 2021;204:626-627.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016